In a single-arm study of PDS0101 and pembrolizumab in the first-line setting for PD-L1-positive, recurrent/metastatic HPV-16-positive HNSCC (n = 53), ORR was 34% and median PFS 6.3 months [101]. Here, CD274 is linked to head and neck squamous cell carcinoma.